Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term antibody persistence after infant Hexaxim versus comparator vaccination
2011-004450-26Phase 3
- Sponsor
- Sanofi
- Start
- Apr 2012
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of hexaxim, Haemophilus b conjugate vaccine, Oral polio vaccine and hepatitis B vaccine recombinant in diphtheria, Tetanus, pertussis and 3 more (2 cohorts), sponsored by Sanofi. Primary endpoints: Long-term serological antibody persistence at 3.5 years of age and Long-term serological antibody persistence at 4.5 years of age.
02
Drugs
hexaximHaemophilus b conjugate vaccineOral polio vaccinehepatitis B vaccine recombinant
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2011-004450-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004450-26.